Pfizer lung cancer drug looks promising in mid-stage study

Pfizer's experimental lung cancer drug PF-299 has garnered some positive reviews after the pharma giant unveiled some promising, though preliminary, mid-stage data. Nearly 85 percent of the patients sharing an EGFR mutation were progress-free after about nine months of therapy.

While researchers have only tracked 74 patients so far, Pfizer is hoping that PF-299 could eventually be added to the pharmaceutical armory used to fight non-small cell lung cancer. Chinese University's Tony Mok says the drug is particularly promising because it can target multiple receptors on the HER pathway, notes Reuters and PharmaTimes, specifically HER 1(EGFR), HER-2 and HER-4.

"It also inhibits signalling in both wild-type and mutant EGFR, including forms of NSCLC that are resistant to EGFR inhibitors such as erlotinib and gefitinib," Mok adds.

- here's the story from Reuters
- and here's the PharmaTimes piece

Suggested Articles

MicuRx nabbed $7.78 million from a nonprofit focused on antimicrobial resistance to push its third antimicrobial program into human trials.

The FDA has handed Scholar Rock a rare pediatric disease designation voucher, which can allow the biotech a speedy review of its SMA med.

The FDA has placed a phase 1/2 trial of Passage Bio’s GM1 gene therapy on clinical hold pending further assessment of the risk of its delivery device.